Search research articles
Contact Us
Filters
Showing results (31-40 of 215) with videos related to
Page
of 22
Sort By:
Expert Opinion on Investigational Drugs
|
October 22, 2002
Therapeutic developments in the treatment of amyotrophic lateral sclerosis
Mandy Jackson, Jerònia Lladó, Jeffrey D Rothstein
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 13, 2014
Preclinical models: needed in translation? A Pro/Con debate
Thomas Philips, Jeffrey D Rothstein, Mahmoud A Pouladi
Trends in Neurosciences
|
June 15, 2014
Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies
Steve Vucic, Jeffrey D Rothstein, Matthew C Kiernan
Biorxiv : the Preprint Server for Biology
|
January 3, 2024
Highly variable molecular signatures of TDP-43 loss of function are associated with nuclear pore complex injury in a population study of sporadic ALS patient iPSNs
Jeffrey D Rothstein, Caroline Warlick, Alyssa N Coyne
Trends in Cell Biology
|
August 31, 2013
Oligodendroglia: metabolic supporters of axons
Brett M Morrison, Youngjin Lee, Jeffrey D Rothstein
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
September 7, 2022
Nuclear Pore Dysfunction in Neurodegeneration
Olivia Spead, Benjamin L Zaepfel, Jeffrey D Rothstein
Brain Research
|
April 17, 2009
Tumor necrosis factor-alpha modulates glutamate transport in the CNS and is a critical determinant of outcome from viral encephalomyelitis
Jessica Carmen, Jeffrey D Rothstein, Douglas A Kerr
Annals of Neurology
|
March 30, 2004
Altered expression of the glutamate transporter EAAT2b in neurological disease
Nicholas J Maragakis, Margaret Dykes-Hoberg, Jeffrey D Rothstein
Nature Reviews. Neuroscience
|
May 7, 2016
The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease
Aaron R Haeusler, Christopher J Donnelly, Jeffrey D Rothstein
Neuroscience Letters
|
February 5, 2003
Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice
Nicholas J Maragakis, Mandy Jackson, Raquelli Ganel, et al.
Page
of 22
Search research articles
Search
Showing results (31-40 of 215) with videos related to
Sort By:
Page
of 22
Expert Opinion on Investigational Drugs
|
October 22, 2002
Therapeutic developments in the treatment of amyotrophic lateral sclerosis
Mandy Jackson, Jerònia Lladó, Jeffrey D Rothstein
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 13, 2014
Preclinical models: needed in translation? A Pro/Con debate
Thomas Philips, Jeffrey D Rothstein, Mahmoud A Pouladi
Trends in Neurosciences
|
June 15, 2014
Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies
Steve Vucic, Jeffrey D Rothstein, Matthew C Kiernan
Biorxiv : the Preprint Server for Biology
|
January 3, 2024
Highly variable molecular signatures of TDP-43 loss of function are associated with nuclear pore complex injury in a population study of sporadic ALS patient iPSNs
Jeffrey D Rothstein, Caroline Warlick, Alyssa N Coyne
Trends in Cell Biology
|
August 31, 2013
Oligodendroglia: metabolic supporters of axons
Brett M Morrison, Youngjin Lee, Jeffrey D Rothstein
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
September 7, 2022
Nuclear Pore Dysfunction in Neurodegeneration
Olivia Spead, Benjamin L Zaepfel, Jeffrey D Rothstein
Brain Research
|
April 17, 2009
Tumor necrosis factor-alpha modulates glutamate transport in the CNS and is a critical determinant of outcome from viral encephalomyelitis
Jessica Carmen, Jeffrey D Rothstein, Douglas A Kerr
Annals of Neurology
|
March 30, 2004
Altered expression of the glutamate transporter EAAT2b in neurological disease
Nicholas J Maragakis, Margaret Dykes-Hoberg, Jeffrey D Rothstein
Nature Reviews. Neuroscience
|
May 7, 2016
The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease
Aaron R Haeusler, Christopher J Donnelly, Jeffrey D Rothstein
Neuroscience Letters
|
February 5, 2003
Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice
Nicholas J Maragakis, Mandy Jackson, Raquelli Ganel, et al.
Page
of 22